Latest News in the pharma Industry

Research & Development

Regen BioPharma sees success in Its pre-clinical small molecule optimization program for NR2F6

Regen BioPharma sees success in Its pre-clinical small molecule optimization program for NR2F6

12 Apr 2017

The company's small molecule drug program is aimed at treating cancer and autoimmune diseases .

Read more 
BMS and Apexigen collaborate to evaluate Opdivo in combination with APX005M in advanced solid tumours

BMS and Apexigen collaborate to evaluate Opdivo in combination with APX005M in advanced solid tumours

12 Apr 2017

Study to evaluate potential of APX005M plus Opdivo to activate antigen-presenting cells in the tumour micro-environment to demonstrate enhanced anti-tumour activity.

Read more 
Lhasa and Optibrium enter research and product development collaboration

Lhasa and Optibrium enter research and product development collaboration

11 Apr 2017

Drug discovery software specialists combine expertise to extend studies into drug metabolism modelling.

Read more 
Phase III study shows Genentech’s Alecensa was superior to crizotinib in a specific type of lung cancer

Phase III study shows Genentech’s Alecensa was superior to crizotinib in a specific type of lung cancer

10 Apr 2017

Results showed that people treated with Alecensa lived significantly longer without their disease progressing compared to crizotinib when given as initial (first-line) treatment.

Read more 
New technology can detect tiny ovarian tumours

New technology can detect tiny ovarian tumours

10 Apr 2017

 “Synthetic biomarkers” could be used to diagnose ovarian cancer months earlier than now possible.

Read more 
Allergan reports topline Phase II data supporting advancement of Botox for the treatment of MDD

Allergan reports topline Phase II data supporting advancement of Botox for the treatment of MDD

9 Apr 2017

Botox is currently being studied as a potential treatment option for adult patients with moderate to severe MDD.

Read more 
Merck receives CRL from the FDA for TECOS study with sitagliptin

Merck receives CRL from the FDA for TECOS study with sitagliptin

7 Apr 2017

CRL relates to Merck's sNDA for Januvia, Janumet and Janumet XR.

Read more 
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications

Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications

6 Apr 2017

ECF843 is a new therapeutic approach and potential first-in-class Rx treatment in dry-eye.

Read more 
Kite presents promising preclinical data from KITE-585, a fully human anti-BCMA CAR T-cell product candidate

Kite presents promising preclinical data from KITE-585, a fully human anti-BCMA CAR T-cell product candidate

5 Apr 2017

Phase I clinical study of KITE-585 in patients with multiple myeloma planned for 2017.

Read more 
Amgen submits applications in the US and Europe to expand current indication for Xgeva

Amgen submits applications in the US and Europe to expand current indication for Xgeva

4 Apr 2017

Applications include data from the largest international trial conducted in multiple myeloma.

Read more 
Novartis drug combination Tafinlar + Mekinist receives EU approval for BRAF V600-positive advanced NSCLC

Novartis drug combination Tafinlar + Mekinist receives EU approval for BRAF V600-positive advanced NSCLC

3 Apr 2017

New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC.

Read more 
BMS and Incyte to advance the combination of Opdivo and Epacadostat into first-line registrational trials

BMS and Incyte to advance the combination of Opdivo and Epacadostat into first-line registrational trials

2 Apr 2017

Companies to initiate Phase III registrational trials in first-line NSCLC across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017.

Read more